by TrN2016_SandWich | Dec 31, 2017 |
Andy McElroy CEO Andy graduated from Churchill College Cambridge in 1980 with a first class degree in Natural Sciences and completed a PhD in synthetic organic chemistry before joining Glaxo as a medicinal chemist in 1983. He spent seven years at the Ware...
by TrN2016_SandWich | Apr 12, 2016 |
Lars Knutsen Lars J.S. Knutsen began his research career at Glaxo Group research, Ware, UK after completing his MA in Chemistry at Oxford. At Glaxo he completed his Ph.D. in C-Nucleoside Medicinal Chemistry, joining Novo Nordisk in 1986. There, he led two CNS...
by TrN2016_SandWich | Apr 12, 2016 |
Dermott O’Callaghan Dermott O’Callaghan has over 9 years experience in the pharmaceutical industry. His focus has been on early drug discovery in neuroscience with an emphasis on ion channels. He has in-depth experience of numerous drug discovery approaches and...
by TrN2016_SandWich | Apr 12, 2016 |
Michael Swedberg Michael D. B. Swedberg, Ph.D. served as an associate director at AstraZeneca R&D, Södertälje, Sweden, since 1996. Michael provides expertise in CNS in vivo pharmacology, abuse liability and safety pharmacology. He interacts and manages...
by TrN2016_SandWich | Apr 12, 2016 |
Jaminder Khinder A highly experienced Drug Development Scientist with 25 years experience in nonclinical drug safety and nonclinical regulatory for small molecules and biotherapeutics at GlaxosmithKline and Pfizer. Expertise in nonclinical project lead roles with...
